← Leaderboards
Gang Lin
Weill Medical Coll Of Cornell Univ
$10,617,809
Attributed
$10,850,871
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,850,871 · 7
By mechanism
R01$8,987,746 · 3
R21$1,863,125 · 4
Top collaborators
- Laura Kirkman2 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Sabine Ehrt$39,683,358
- Laura Kirkman$3,962,426
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsMulticatalytic Endopeptidase ComplexPeptidesProteasome InhibitorCessation Of LifeDrug KineticsIn VivoIn VitroResistanceProteinsMalariaReportingDrug ResistanceParasitesPlasmodium FalciparumGlobal HealthChildPropertyToxic EffectOralMutationActive SitesLead OptimizationEnzymes
Grant awards (21)
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials$798,289
R01 · FY2025 · AI · contact PI
Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance$749,775
R01 · FY2025 · AI · contact PI
Novel proteasome inhibitors targeting both beta5 and beta2 subunits for treatment of triple negative breast cancer$643,772
R01 · FY2025 · CA · contact PI
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials$845,899
R01 · FY2024 · AI · contact PI
Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance$735,318
R01 · FY2024 · AI · contact PI
Novel proteasome inhibitors targeting both beta5 and beta2 subunits for treatment of triple negative breast cancer$661,147
R01 · FY2024 · CA · contact PI
Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance$96,578
R01 · FY2024 · AI · contact PI
Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance$752,693
R01 · FY2023 · AI · contact PI
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials$737,380
R01 · FY2023 · AI · contact PI
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials$737,380
R01 · FY2022 · AI · contact PI
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials$737,380
R01 · FY2021 · AI · contact PI
Compounds that force Plasmodium falciparum to produce its own inhibitors$254,250
R21 · FY2021 · AI · contact PI
Macrocyclic proteasome inhibitors for treatment of tuberculosis$254,250
R21 · FY2021 · AI · contact PI
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials$737,380
R01 · FY2020 · AI · contact PI
Compounds that force Plasmodium falciparum to produce its own inhibitors$211,875
R21 · FY2020 · AI · contact PI
Macrocyclic proteasome inhibitors for treatment of tuberculosis$211,875
R21 · FY2020 · AI · contact PI
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials$754,755
R01 · FY2019 · AI · contact PI
Novel Inhibitors of Malaria Proteasome$211,875
R21 · FY2018 · AI · contact PI
Novel Inhibitors of Malaria Proteasome$254,250
R21 · FY2017 · AI · contact PI
Species selective dipeptide inhibitors for Mtb proteasome$211,250
R21 · FY2014 · AI · contact PI
Species selective dipeptide inhibitors for Mtb proteasome$253,500
R21 · FY2013 · AI · contact PI